Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation.

[1]  M. Enriquez-Sarano,et al.  Quantitative Determinants of the Outcome of Asymptomatic Mitral Regurgitation , 2005 .

[2]  G. Vitale,et al.  Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass , 2004, Clinical endocrinology.

[3]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[4]  Jeroen J. Bax,et al.  Increased prevalence of regurgitant valvular heart disease in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[5]  D. Bonaduce,et al.  High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  R. Clayton.  Cardiovascular function in acromegaly. , 2003, Endocrine reviews.

[7]  C. Mady,et al.  Treatment of acromegaly improves myocardial abnormalities. , 2002, American heart journal.

[8]  P. Libby,et al.  Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves , 2001, Circulation.

[9]  B. Howard,et al.  Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. , 2001, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[10]  M. Salvatore,et al.  Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. , 2001, The Journal of clinical endocrinology and metabolism.

[11]  B. Thompson,et al.  Identification of genes induced by growth hormone in rat liver using cDNA arrays. , 2000, Endocrinology.

[12]  I. Lancranjan,et al.  Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. , 2000, The Journal of clinical endocrinology and metabolism.

[13]  Jagmeet P. Singh,et al.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.

[14]  L. Saccá,et al.  Growth Hormone and the Heart , 1999, Mineral and Electrolyte Metabolism.

[15]  A. Gulino,et al.  Echocardiographic evidence for a direct effect of GH/IGF‐I hypersecretion on cardiac mass and function in young acromegalics , 1998, Clinical endocrinology.

[16]  J. Thomas.  How leaky is that mitral valve? Simplified Doppler methods to measure regurgitant orifice area. , 1997, Circulation.

[17]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[18]  N C Nanda,et al.  Evaluation of aortic insufficiency by Doppler color flow mapping. , 1987, Journal of the American College of Cardiology.

[19]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[20]  N. Reichek.  Echocardiographic assessment of left ventricular hypertrophy. , 1982, European heart journal.

[21]  J. Alpert,et al.  Primary myxomatous degeneration of cardiac valves. Clinical, pathological, haemodynamic, and echocardiographic profile. , 1980, British heart journal.

[22]  J. W. Pate,et al.  Myxomatous degeneration of cardiac valves. , 1970, Chest.